All-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) is the standard of care for acute promyelocytic leukemia (APL), including high-risk disease. Secondary intracranial hypertension (SIH), historically termed pseudotumor cerebri (PTC), is a recognized but uncommon and potentially therapy-limiting complication of retinoid exposure, reported predominantly in pediatric and young-adult patients and most...
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change for audiology practice; this case report addresses a rare neurological drug complication in oncology with minimal direct relevance to routine audiological care.
Audiologists involved in oncology teams should be aware that ATRA/ATO therapy can cause intracranial hypertension, which may present with auditory or vestibular symptoms requiring multidisciplinary evaluation.
- 01Single case report of secondary intracranial hypertension (high brain pressure) during ATRA/arsenic trioxide leukemia treatment.
- 02ATRA/ATO therapy is used for high-risk acute promyelocytic leukemia, a blood cancer.
- 03Intracranial hypertension can occasionally cause hearing or balance symptoms, indirectly relevant to audiology.
- 04Authors propose a practical management framework for this complication.
- 05Published in Current Oncology; evidence level is low (case report).
ATRA/arsenic trioxide therapy for acute promyelocytic leukemia can cause secondary intracranial hypertension.
studypartially supported- PMID
- 42930178
- DOI
- 10.3390/curroncol33100611.
- Journal
- Current Oncology
- Publication type
- case_report
- Evidence level
- 4
- Sample size
- 1
- Population
- Adult patient with high-risk acute promyelocytic leukemia receiving ATRA/ATO therapy
- Intervention
- ATRA/arsenic trioxide (ATO) combination therapy
Primary outcomes
Occurrence and management of secondary intracranial hypertension